Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.22 (HKD) • At close September 19, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Clover Biopharmaceuticals, Ltd. |
Symbool | 2197.HK |
Munteenheid | HKD |
Prijs | 0.218 |
Beurswaarde | 282,756,650 |
Dividendpercentage | 0% |
52-weken bereik | 0.201 - 0.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Joshua G. Liang |
Website | https://www.cloverbiopharma.com |
An error occurred while fetching data.
Over Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)